CJC 1295 No Dac + Ipamorelin

Description

CJC-1295 No DAC + Ipamorelin

Lyophilized Powder | Third-Party Tested | USA-Manufactured

In Stock | Free Shipping on Orders Over $150

---

Product Specifications

• Peptide Name: CJC-1295 No DAC + Ipamorelin
• Molecular Formula: CJC-1295 (No DAC): C152H252N44O42 | Ipamorelin: C38H49N9O5
• Molecular Weight: CJC-1295 (No DAC): ~3367.9 g/mol | Ipamorelin: ~711.9 g/mol
• CAS Number: CJC-1295 (No DAC): 863288-34-0 | Ipamorelin: 170851-70-4
• Sequence: CJC-1295 (No DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys
• Purity: ≥99% (HPLC verified)
• Form: Lyophilized powder
• Storage: -20°C (long-term) | 2–8°C (short-term) | Protect from light
• Shelf Life: Up to 12 months when stored sealed and dry

---

Compound Overview

CJC-1295 No DAC + Ipamorelin is a combined-vial peptide formulation composed of two structurally distinct synthetic research peptides. CJC-1295 (No DAC) is a modified growth hormone-releasing hormone class peptide analog defined by a linear amino acid sequence, while Ipamorelin is a short peptide sequence containing non-proteinogenic residues that influence conformational and analytical behavior in laboratory characterization workflows.

In laboratory research contexts, dual-peptide formulations are evaluated for identity confirmation, stability profiling, and analytical separation of component peptides using chromatographic and mass spectrometry workflows under validated protocols. Experimental literature describes both GHRH-class peptide analogs and short secretagogue-class peptide sequences as research tools in controlled in vitro and preclinical animal models. All data referenced on this page is derived from published preclinical animal and in vitro studies. No human clinical trials have established approved uses for CJC-1295 No DAC + Ipamorelin as a research compound.

---

Published Preclinical Research

Published literature describes GHRH-class peptide analogs and short secretagogue-class peptide sequences as defined research compounds investigated within controlled experimental systems.

• Structural characterization and receptor interaction mapping in preclinical laboratory models
• Analytical detection and identity confirmation using LC-MS and chromatographic profiling workflows
• Peptide stability and degradation profiling in controlled biological matrices
• Comparative evaluation of multi-analyte peptide panels in validated experimental systems

All data referenced on this page is derived from published preclinical animal and in vitro studies. No human clinical trials have established approved uses for CJC-1295 No DAC + Ipamorelin.

---

Research Applications

• Dual-peptide identity confirmation using LC-MS workflows
• Method development for separating and quantifying blended peptide components
• Analytical reference benchmarking for peptide hormone research panels
• In vitro receptor interaction modeling under controlled laboratory conditions
• Stability profiling of multi-peptide preparations in validated matrices

---

Physical Specifications

• Vial Size: 3 mL sterile vial
• Fill: 5mg CJC-1295 (No DAC) / 5mg Ipamorelin
• Appearance: White to off-white lyophilized powder
• Reconstitution Volume: Researcher-determined under validated laboratory protocols
• Post-Reconstitution Storage: 2–8°C, use within 30 days
• Solubility: Water-based laboratory solvents

---

Compare to Related Compounds

CJC-1295 No DAC

• CJC-1295 No DAC + Ipamorelin contains CJC-1295 (No DAC) as one component peptide, whereas CJC-1295 No DAC (10mg) is supplied as a single-peptide vial within the same structural class.
• Single-peptide and blended-peptide formats are differentiated in laboratory workflows by analytical separation requirements and component verification steps.

Ipamorelin

• CJC-1295 No DAC + Ipamorelin contains Ipamorelin as one component peptide, whereas Ipamorelin (10mg) is supplied as a standalone peptide vial with a distinct short-sequence structural framework.
• Analytical characterization focuses on confirming identity of each component peptide and verifying purity within blended or single-compound preparations.

Tesamorelin

• CJC-1295 No DAC + Ipamorelin is a dual-peptide formulation combining a GHRH analog and a short secretagogue peptide, whereas Tesamorelin is a single stabilized GHRH analog with a distinct 44–amino acid sequence framework.
• These compounds differ in sequence length, structural modification profile, and analytical characterization in validated peptide workflows.

IGF-1 LR3

• CJC-1295 No DAC + Ipamorelin is classified within growth hormone–axis peptide research systems, whereas IGF-1 LR3 is a long-chain insulin-like growth factor analog with a distinct receptor classification and molecular architecture.
• Analytical differentiation focuses on molecular weight, sequence length, and receptor pathway classification in controlled laboratory models.

---

Handling & Storage

Lyophilized Stability:
When stored sealed in a dry environment protected from light, lyophilized peptide material may maintain chemical stability for up to 12 months at controlled room temperature. For maximum long-term preservation, storage at -20°C is recommended.

Post-Reconstitution Stability:
Following reconstitution under sterile laboratory conditions, the solution may maintain stability for up to 30 days when stored at 2–8°C. Minimize repeated freeze–thaw cycles and protect from light to preserve peptide integrity.

Handling:
Allow vial to equilibrate to room temperature before opening to prevent moisture condensation. Use sterile technique throughout preparation.

---

Certificate of Analysis & Third-Party Testing

Every batch of BioEdge CJC-1295 No DAC + Ipamorelin undergoes independent third-party testing prior to release. Testing is performed by ISO-accredited laboratories with results available on each product page.

Identity Confirmation	Mass Spectrometry (MS)
Purity Assessment	High-Performance Liquid Chromatography (HPLC)
Minimum Purity Acceptance	≥99%
Heavy Metals	ICP-MS panel
Sterility	USP <71> Sterility Testing
COA Format	Batch-specific test results, downloadable on product page

To view testing results, scroll to the 3rd Party Testing section located below the product image.

---

Why Researchers Choose BioEdge for CJC-1295 No DAC + Ipamorelin

Batch-specific COA from an independent lab. Not a generic PDF recycled across products. Every vial of CJC-1295 No DAC + Ipamorelin is backed by independent third-party laboratory testing, with a Certificate of Analysis available for review on our product page. HPLC confirms purity. Mass spectrometry confirms molecular identity. The COA corresponds to the specific batch you receive.

USA lyophilization. Many vendors import pre-filled vials from overseas and relabel them. BioEdge sources API and performs lyophilization within the United States, maintaining direct quality control over the final product.

No filler compounds. BioEdge CJC-1295 No DAC + Ipamorelin is pure lyophilized peptide. No mannitol, no bulking agents, no unnecessary excipients.

Same-day shipping. Domestic orders placed before 3pm ship the same day. Free shipping on orders over $150.

---

Frequently Asked Questions

What is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin is a combined-vial peptide formulation containing two synthetic research peptides supplied exclusively for laboratory research use.

What is the CAS number for CJC-1295 No DAC + Ipamorelin?

CJC-1295 (No DAC): 863288-34-0 | Ipamorelin: 170851-70-4

How should CJC-1295 No DAC + Ipamorelin be stored?

Store sealed in a dry environment protected from light. For maximum long-term preservation, storage at -20°C is recommended.

Is CJC-1295 No DAC + Ipamorelin third-party tested?

Yes. Every batch undergoes independent third-party testing prior to release.

Where can I access the COA for CJC-1295 No DAC + Ipamorelin?

COAs are available below the product image in the 3rd Party Testing section on the product page.

Is CJC-1295 No DAC + Ipamorelin FDA approved?

BioEdge CJC-1295 No DAC + Ipamorelin is sold strictly as a research compound for in vitro laboratory use. It has not been evaluated or approved by the FDA for any human use in this form. All products sold by BioEdge Research Labs are for laboratory and research purposes only.

Do you ship CJC-1295 No DAC + Ipamorelin within the USA?

Yes. BioEdge Research Labs is a USA based supplier with same day domestic shipping on orders placed before 3pm Eastern. Free shipping on orders over $150.

Can I get bulk pricing on CJC-1295 No DAC + Ipamorelin?

Yes. Contact BioEdge Research Labs directly for institutional and bulk research pricing.

---

Published References

1. Veldhuis JD, et al. “Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Elevation of GH Concentrations after Administration of a Long-Acting GH-Releasing Hormone Analog (CJC-1295).” The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. Link

2. Frohman LA, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. Link

3. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552-561. Link

4. Johansson PI, et al. “Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus.” The American Journal of Gastroenterology. 2008;103(8):2043-2050. Link

---

RESEARCH USE ONLY Disclaimer

RESEARCH USE ONLY. CJC-1295 No DAC + Ipamorelin is sold exclusively for in vitro laboratory and research purposes. This product is not intended for human or animal consumption, clinical use, or therapeutic application. It has not been evaluated by the Food and Drug Administration (FDA) for safety, efficacy, or any medical purpose. Purchase and use of this product confirms the buyer will use it only in qualified research settings, in compliance with all applicable federal, state, and local regulations. BioEdge Research Labs is a chemical supplier, not a compounding pharmacy or clinical facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. BioEdge Research Labs makes no claims regarding therapeutic, diagnostic, or clinical applications of this compound.